Business Segments · Operating Income (Loss), Adjusted
MedSurg — Operating Income (Loss), Adjusted
Boston Scientific MedSurg — Operating Income (Loss), Adjusted increased by 1.6% to $575.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.4%, from $521.00M to $575.00M. Over 3 years (FY 2022 to FY 2025), MedSurg — Operating Income (Loss), Adjusted shows an upward trend with a 15.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ1 2022
Last reportedQ4 2025
How to read this metric
An increase indicates improved core profitability and operational leverage within the segment.
Detailed definition
Measures the profitability of the MedSurg segment by excluding non-recurring items, restructuring charges, and other adj...
Peer comparison
Commonly referred to as 'Adjusted Segment Operating Profit' or 'Segment EBIT' among medical device peers.
Metric ID:
bsx_segment_medsurg_operating_income_loss_adjustedHistorical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $372.25M | $372.25M | $372.25M | $372.25M | $458.50M | $458.50M | $458.50M | $458.50M | $485.00M | $522.00M | $518.00M | $521.00M | $528.00M | $599.00M | $566.00M | $575.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +23.2% | +0.0% | +0.0% | +0.0% | +5.8% | +7.6% | -0.8% | +0.6% | +1.3% | +13.4% | -5.5% | +1.6% |
| YoY Change | — | — | — | — | +23.2% | +23.2% | +23.2% | +23.2% | +5.8% | +13.8% | +13.0% | +13.6% | +8.9% | +14.8% | +9.3% | +10.4% |
Range$372.25M – $599.00M
CAGR+12.3%
Avg YoY Growth+15.2%
Median YoY Growth+13.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's medsurg — operating income (loss), adjusted?
- Boston Scientific (BSX) reported medsurg — operating income (loss), adjusted of $575.00M in Q4 2025.
- How has Boston Scientific's medsurg — operating income (loss), adjusted changed year-over-year?
- Boston Scientific's medsurg — operating income (loss), adjusted increased by 10.4% year-over-year, from $521.00M to $575.00M.
- What is the long-term trend for Boston Scientific's medsurg — operating income (loss), adjusted?
- Over 3 years (2022 to 2025), Boston Scientific's medsurg — operating income (loss), adjusted has grown at a 15.1% compound annual growth rate (CAGR), from $1.49B to $2.27B.
- What does medsurg — operating income (loss), adjusted mean?
- The core operating profit of the MedSurg segment, excluding one-time or non-operational charges.